Abstract: The present invention relates to a method of preparation of ?-galactosyl ceramides compounds of formula (I): comprising a step a) of glycosylation of a compound of formula (II): with a compound of formula (III):
Abstract: The invention relates to processes for preparing (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside and compositions comprising the same.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
December 22, 2020
Assignees:
THE SCRIPPS RESEARCH INSTITUTE, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Melpo Christofidou-Solomidou, Kyriacos C. Nicolaou, Roman A. Valiulin, Nicholas Simmons, Philipp M. Heretsch
Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
December 1, 2020
Assignees:
Pfizer Inc., The Regents of the University of California
Inventors:
Spiros Liras, Vincent Mascitti, Benjamin Aaron Thuma, Jennifer A. Doudna, Romain Rouet
Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
November 24, 2020
Assignee:
ALTERGON S.A.
Inventors:
Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
Abstract: Though 3?,5?-cyclic diadenylic acid was conventionally provided only as a freeze-dried product, a solid material other than a freeze-dried product and a manufacturing method thereof is provided. By a step of adding acid to an aqueous solution of 3?,5?-cyclic diadenylic acid so as to lower pH to 1 to 3, an inclusion compound of 3?,5?-cyclic diadenylic acid can be obtained. Said manufacturing method is an extremely simple and easy method and does not need a special machine or the like.
Abstract: The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.
Type:
Grant
Filed:
May 14, 2018
Date of Patent:
November 3, 2020
Assignee:
PHYTO CORPORATION INC.
Inventors:
Deuk-Hoi Kim, Mee-Hyang Kweon, Eun-Ah Cho, Joon Soo Kim, Hyun Joo Yoon, Seon Yeong Park
Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
Abstract: Various ingredients and compositions are prepared from Stevia rebaudiana Bertoni plant. The compositions can be used as bulking agents, and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
Type:
Grant
Filed:
July 31, 2018
Date of Patent:
October 13, 2020
Assignee:
UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
Inventors:
Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
Abstract: An object of the present invention is to provide glycoamino acid as an amino acid precursor with improved properties (particularly water-solubility, stability in water, bitter taste etc.). The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
Abstract: A crystal of free acid of 3?,5?-cyclic diguanylic acid containing no metal salt with cobalt, magnesium or the like is provided. A method is sought for obtaining said crystal in a large amount and with ease. By a manufacturing method comprising a step of adding acid to an aqueous solution of 3?,5?-cyclic diguanylic acid so as to lower pH to 1 to 3, crystals of 3?,5?-cyclic diguanylic acid can be obtained in a large amount with ease. Said crystals are free acid crystals which do not contain a metal salt with cobalt, magnesium or the like.
Abstract: Single-chain ?-glucans can be obtained by hydrothermal treatment of a solution containing (1,3)(1,6)-?-glucan for a predetermined time in a temperature range of from 145° C. to 200° C. at a pressure at or above the saturated vapor pressure at the treatment temperature. ?-Glucans capable of maintaining a single-chain state for an extended period of time can be produced without chemical treatment.
Abstract: A nacre-mimetic environmentally friendly composite membrane with an “interpenetrating petal” structure and a preparation method thereof. Materials for preparing the composite membrane include magadiite, CMC and a bis-silane coupling agent. The composite membrane according to the present invention has an “interpenetrating petal” stable structure with non-parallel petal-shaped lamellar structure. In addition, inorganic sheets intersperse with each other to form an interlock.
Abstract: Described herein are methods and compositions that contain a soluble polyglucosamine or polyglucosamine derivative for use in oral health. The compositions are useful for, e.g., reducing bacteria (e.g., by clumping and removing) or disrupting a biofilm in the mouth of a subject, reducing dry mouth, and reducing oral inflammation.
Type:
Grant
Filed:
April 9, 2018
Date of Patent:
September 8, 2020
Assignee:
SYNEDGEN, INC.
Inventors:
Stacy M. Townsend, Shenda M. Baker, William P. Wiesmann
Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
Abstract: Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.
Type:
Grant
Filed:
July 17, 2018
Date of Patent:
September 1, 2020
Assignee:
NOVINTETHICAL PHARMA SA
Inventors:
Miguel Angel Alonso Cohen, Michele Giuseppe Di Schiena, Marco Di Fulvio
Abstract: An object of the present invention is to provide a crystal of 6?-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.
Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
Type:
Grant
Filed:
March 20, 2019
Date of Patent:
August 4, 2020
Assignee:
Piedmont Animal Health Inc.
Inventors:
Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler, Raymond Petzold